We are live on
!
Find out more
PHS
PFM Health Sciences Portfolio holdings
AUM
$1.17B
1-Year Est. Return
92.19%
This Fund
S&P 500
This Quarter
Est. Return
-5.2%
1 Year Est. Return
+92.19%
3 Year Est. Return
+240.57%
5 Year Est. Return
+377.11%
10 Year Est. Return
+3,179.38%
AUM
$3.55B
AUM Growth
-$395M
(-10%)
Cap. Flow
-$144M
Cap. Flow
% of AUM
-4.06%
Top 10 Holdings %
Top 10 Hldgs %
43.38%
Holding
114
New
26
Increased
23
Reduced
23
Closed
40
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$187M |
| 2 |
Pfizer
PFE
|
+$168M |
| 3 |
Gilead Sciences
GILD
|
+$125M |
| 4 |
UnitedHealth
UNH
|
+$125M |
| 5 |
Eli Lilly
LLY
|
+$93.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Elevance Health
ELV
|
+$84.3M |
| 2 |
Apple
AAPL
|
+$80.7M |
| 3 |
BRCM
BROADCOM CORP CL-A
BRCM
|
+$75.5M |
| 4 |
Liberty Global Class C
LBTYK
|
+$74M |
| 5 |
VMW
VMware, Inc
VMW
|
+$72.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 65.95% |
| 2 | Communication Services | 6.34% |
| 3 | Financials | 5.66% |
| 4 | Technology | 4.95% |
| 5 | Consumer Discretionary | 4.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CLVS
1
DELISTED
Clovis Oncology, Inc.
CLVS
| $235M | 6.6% |
2,552,887
-160,774
| -6% | -$13.9M |
|
2
HCA Healthcare
HCA
$87.7B
| $183M | 5.15% |
2,367,026
+321,743
| +16% | +$28.5M |
|
|
WBA
3
DELISTED
Walgreens Boots Alliance
WBA
| $179M | 5.05% |
2,159,167
+587,146
| +37% | +$53.1M |
|
|
4
UnitedHealth
UNH
$356B
| $170M | 4.78% |
1,465,502
+1,042,438
| +246% | +$125M |
|
|
5
Pfizer
PFE
$162B
| $166M | 4.66% |
5,564,481
+5,232,819
| +1,578% | +$168M |
|
|
AGN
6
DELISTED
Allergan plc
AGN
| $165M | 4.65% |
+608,789
| New | +$187M |
|
7
Bristol-Myers Squibb
BMY
$136B
| $123M | 3.46% |
2,075,777
-28,191
| -1% | -$1.79M |
|
8
Edwards Lifesciences
EW
$51.8B
| $112M | 3.15% |
4,724,580
-638,358
| -12% | -$15.4M |
|
|
9
Gilead Sciences
GILD
$187B
| $111M | 3.11% |
+1,125,974
| New | +$125M |
|
10
Meta Platforms (Facebook)
META
$1.57T
| $98.2M | 2.76% |
1,092,146
+79,514
| +8% | +$7.3M |
|
11
Palo Alto Networks
PANW
$272B
| $92.9M | 2.61% |
3,239,106
+863,106
| +36% | +$25.5M |
|
|
12
Eli Lilly
LLY
$1.02T
| $92.6M | 2.6% |
+1,106,139
| New | +$93.4M |
|
13
Teva Pharmaceuticals
TEVA
$42.4B
| $86.9M | 2.44% |
1,538,865
+329,901
| +27% | +$21.4M |
|
14
Vulcan Materials
VMC
$34B
| $82.9M | 2.33% |
929,900
-114,854
| -11% | -$10.7M |
|
15
AerCap
AER
$22.9B
| $80.1M | 2.25% |
2,093,991
-1,047,764
| -33% | -$46.3M |
|
16
Heron Therapeutics
HRTX
$65.3M
| $72.3M | 2.03% |
2,962,656
+1,151,490
| +64% | +$38.4M |
|
|
AET
17
DELISTED
Aetna Inc
AET
| $70.3M | 1.98% |
642,915
-137,015
| -18% | -$15.8M |
|
18
ServiceNow
NOW
$146B
| $69.2M | 1.95% |
4,984,360
+1,279,340
| +35% | +$19.1M |
|
|
BRCM
19
DELISTED
BROADCOM CORP CL-A
BRCM
| $65.4M | 1.84% |
1,271,730
-1,466,693
| -54% | -$75.5M |
|
20
Universal Health Services
UHS
$10B
| $64.6M | 1.82% |
517,243
+9,802
| +2% | +$1.36M |
|
21
Home Depot
HD
$320B
| $60.8M | 1.71% |
+526,343
| New | +$60.9M |
|
|
MIC
22
DELISTED
Macquarie Infrastructure Holdings, LLC
MIC
| $59.6M | 1.68% |
798,443
-309,043
| -28% | -$24.7M |
|
23
Booking.com
BKNG
$145B
| $56.7M | 1.6% |
+1,146,950
| New | +$57M |
|
|
HOLX
24
DELISTED
Hologic
HOLX
| $54.9M | 1.54% |
1,403,438
-520,324
| -27% | -$20.6M |
|
|
MDCO
25
DELISTED
Medicines Co
MDCO
| $49M | 1.38% |
1,289,652
-12,864
| -1% | -$452K |
|
Similar funds
JC
PRS
MK
HCP
EC
M
CCM
VFP
PFM Health Sciences's Q3 2015 Portfolio in Review
As of Q3 2015, PFM Health Sciences held 114 positions worth $3.55B, down 10% from $3.95B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
PFM Health Sciences withdrew a net $144M in Q3 2015, closing 40 positions and reducing 23 holdings. Its most notable exit was Elevance Health, an estimated $84.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 66% of assets, up from 53% a quarter earlier, followed by Communication Services and Financials.
Against the trend, PFM Health Sciences opened a new position in Allergan plc worth $165M.
- PFM Health Sciences's largest Q3 2015 buy was Allergan plc: 608,789 shares worth $165M.
- PFM Health Sciences added most to Pfizer in Q3 2015, an estimated $168M increase.
- PFM Health Sciences's biggest Q3 2015 reduction was BROADCOM CORP CL-A, cutting an estimated $75.5M.
- PFM Health Sciences fully exited Elevance Health in Q3 2015, selling an estimated $84.3M.
- PFM Health Sciences's ten largest holdings make up 43% of its $3.55B portfolio in Q3 2015.
- PFM Health Sciences opened 26 new positions and closed 40 in Q3 2015.
- PFM Health Sciences's portfolio value fell 10% quarter-over-quarter to $3.55B.
Based on PFM Health Sciences's 13F filing for Q3 2015, filed 16 Nov 2015.